购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

SB 525334

Rating icon 很棒
产品编号 T1763Cas号 356559-20-1
别名 SB525334

SB525334是转化生长因子β1受体 (ALK5) 选择性抑制剂,IC50=14.3 nM。

SB 525334
TargetMol

为众多的药物研发团队赋能,

让新药发现更简单!

SB 525334

Rating icon 很棒
纯度: 99.86%
产品编号 T1763 别名 SB525334Cas号 356559-20-1

SB525334是转化生长因子β1受体 (ALK5) 选择性抑制剂,IC50=14.3 nM。

规格价格库存数量
1 mg¥ 112现货
5 mg¥ 239现货
10 mg¥ 411现货
25 mg¥ 873现货
50 mg¥ 1,550现货
100 mg¥ 2,390现货
200 mg¥ 2,730现货
大包装 & 定制
加入购物车
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
实验操作小课堂
常见问题解答
查看更多

"SB 525334"的相关化合物库

选择批次:
纯度:≥95%
联系我们获取更多批次信息

产品介绍

生物活性
产品描述
SB-525334 is a potent and selective inhibitor of the TGF-β1R and ALK5 (IC50: 14.3 nM).
靶点活性
ALK4:58.5 nM, ALK5:14.3 nM (cell free)
体外活性
SB-525334(1 μM)在肾小管近端细胞中阻断了TGF-beta1诱导的Smad2/3的磷酸化和核内转移,并抑制了TGF-beta1在A498肾上皮癌细胞中诱导的纤溶酶原激活物抑制剂-1(PAI-1)及前胶原α1(I) mRNA表达的增加[1]。与SB525334的联合应用显著增强了在亲本细胞和耐古美替尼的胰腺癌细胞中古美替尼的细胞毒性。SB525334在耐古美替尼的细胞中显著增加了凋亡细胞死亡[2]。
体内活性
口服给予1、3或10 mg/kg/day的SB 525334,连续11天,能显著降低肾脏PAI-1 mRNA表达[1]。SB 525334(10 mg/kg或30 mg/kg)每日两次口服。在Bleomycin(BLM)处理后的第5、7、9和14天,分离肺部进行研究。BLM处理导致显著的肺纤维化变化,伴随ECM mRNA表达显著上调、Smad2/3核转位、CTGF表达增加、肌成纤维细胞增殖以及I型胶原沉积。SB 525334处理减轻了肺部的组织病理学改变,并显著降低了I型和III型前胶原及纤维连接蛋白mRNA表达[3]。
激酶实验
To determine the potency of the ALK5 inhibitor SB-525334 at the enzyme level, purified GST-tagged kinase domain of ALK5 was incubated with purified GST-tagged full-length Smad3 in the presence of 33P-γATP and different concentrations of SB525334. The readout is radioactively labeled Smad3. To determine the selectivity of SB-525334, purified GST-tagged kinase domain of ALK2 and ALK4 were incubated with GST-tagged full-length Smad1 and Smad3, respectively, in the presence of different concentrations of SB-525334 (n=3). IC50 value determinations were calculated with GraphPad software using a sigmoidal dose-response curve [1].
细胞实验
RPTE cells were seeded on microscope slides. The following day, the cells were starved by removal of epidermal growth factor and serum for 24 h prior to dosing. Cells were dosed with 10 ng/ml TGF- 1 or 1 M SB-525334 or a combination of both. Slides were pretreated with SB-525334 or starve media for 3 h prior to a 1-h incubation at 37°C with TGF- 1 or starve media. The cells were then fixed for 15 min in 4% ice-cold paraformaldehyde. The cells were permeabilized for 10 min in 0.3% Triton X-100/PBS at room temperature. The slides were incubated for 30 min in a blocking solution containing 0.3% bovine serum albumin, 10% FBS, 0.3% Triton X-100/PBS, and 5% milk in PBS. A 1:200 dilution of primary mouse anti-Smad2/3 antibody was applied to each slide for overnight incubation. A 1:200 dilution of anti-mouse IgG fluorescein secondary antibody was applied to each slide for 30 min at room temperature. The slides were then viewed using an argon blue 488 nM laser in a confocal microscope. Nuclear signal intensity was analyzed using 1D Image Analysis software. The relative intensity was determined by the mean intensity of the nucleus and expressed as percent control [1].
动物实验
To identify the optimal treatment length for puromycin aminonucleoside's effect on extracellular matrix in the kidney, 18 Sprague-Dawley (SD) rats (200 –250 g) were injected with 15 mg/100 g of puromycin aminonucleoside in 0.9% saline or sham 0.9% saline only intraperitoneally. Animals were sacrificed at 24 h (n = 3+2 control), day 4 (n=3), day 8 (n = 3), day 10 (n = 3), day 15 (n = 2), and day 20 (n = 2). A 24-h urine collection and plasma sample were taken at 9:00 AM everyday. Urine and plasma chemistry were measured at GlaxoSmithKline Laboratories Animal Science using an Olympus clinical analyzer. Proteinuria was measured as a concentration (mg/deciliter) and then converted to total protein excreted over a 24-h period using urine flow (mL/24 h). The creatinine clearance was calculated by multiplying urine creatinine levels (mg/mL) by urine flow (mg/mL/100 g b.wt.) and then dividing that product by plasma creatinine (mg/mL). To determine the effect of SB-525334 on renal disease in the PAN model, SD rats were pretreated by oral gavage with 1, 3, or 10 mg/kg/day of SB-525334 once a day. The following day, PAN was injected at 15 mg/100 g to the appropriate rats. Treatment groups continued to receive SB-525334. Ten days after PAN injection the rats were sacrificed, and blood, urine, and kidneys were collected at the termination point for analysis [1].
别名SB525334
化学信息
分子量343.42
分子式C21H21N5
CAS No.356559-20-1
SmilesC(C)(C)(C)C=1NC(=C(N1)C=2N=C(C)C=CC2)C3=CC4=C(C=C3)N=CC=N4
密度1.191 g/cm3
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: <1 mg/mL (insoluble or slightly soluble)
1eq. HCl: 34.3 mg/mL (100 mM)
溶液配制表
1eq. HCl
1mg5mg10mg50mg
1 mM2.9119 mL14.5594 mL29.1189 mL145.5943 mL
5 mM0.5824 mL2.9119 mL5.8238 mL29.1189 mL
10 mM0.2912 mL1.4559 mL2.9119 mL14.5594 mL
20 mM0.1456 mL0.7280 mL1.4559 mL7.2797 mL
50 mM0.0582 mL0.2912 mL0.5824 mL2.9119 mL
100 mM0.0291 mL0.1456 mL0.2912 mL1.4559 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy SB 525334 | purchase SB 525334 | SB 525334 cost | order SB 525334 | SB 525334 chemical structure | SB 525334 in vivo | SB 525334 in vitro | SB 525334 formula | SB 525334 molecular weight